97 lakh shares, equivalent to around 6% equity, in Gland Pharma for an estimated Rs 2,800 crore through a block deal, according to the exchange data. 77% stake, in the pharmaceutical company as of the quarter ended June 30, 2026, as per BSE data.

Kotak Mahindra Mutual Fund, Axis Mutual Fund and ICICI Prudential Mutual Fund were among the buyers. 82% stake, for Rs 384 crore.

63% stake, for Rs 294 crore. 6 per share.

90. The stock had fallen to a low of Rs 2,827 during the session following the block deal..

The inspection concluded with zero Form 483 observations. On August 10, Gland Pharma reported a consolidated net profit of Rs 317 crore for Q1FY27, up 47% year-on-year from Rs 216 crore in the corresponding quarter last year.

Revenue from operations rose 20% year-on-year to Rs 1,800 crore from Rs 1,506 crore in Q1FY26. 2 crore, while adjusted EBITDA increased 37% year-on-year.

The adjusted EBITDA margin stood at 28%. The CDMO business contributed 50% of total revenue and recorded 20% year-on-year growth during the quarter.

The B2B business accounted for the remaining 50% of revenue and grew 19% year-on-year. Established in Hyderabad in 1978, Gland Pharma has grown from a contract manufacturer of small-volume liquid parenteral products to a generic injectable manufacturing company with a global footprint across 60 countries, including the United States, Europe, Canada, Australia, India and other markets.

The company primarily operates under a business-to-business (B2B) model and has a track record in pharmaceutical research and development, manufacturing and marketing of complex injectables.